A. Browne

The applicant generic drug manufacturers brought an urgent motion under s. 6(2) of the Judicial Review Procedure Act to proceed with an application for judicial review before a single judge of the Divisional Court.

The applicants alleged that a competitor had obtained an unfair advantage regarding the upcoming release of a new schedule for the drug formulary.

The court found that the applicants would suffer irreparable harm due to the permanent loss of market share associated with the first-to-market advantage, and that the prerequisites of s. 6(2) were met.

The application for judicial review was permitted to continue.

The applicants brought applications for judicial review.

During the hearing, counsel for a third party requested an adjournment to review the filings and potentially seek intervenor status, as the third party had not been served.

The court granted the adjournment to allow the third party to decide whether to intervene.

The court also issued an interim order delaying the effective date of the third party's generic drug listings pending the resumption of the hearing.